Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Regulatory News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

Share Price is delayed by 15 minutes
Get Live Data
8.35    -0.10 (-1.18%)
Bid:
8.10
Ask:
8.60
Spread: 0.50 (6.173%)
Market Cap: £59.23m
POLB Live PriceLast checked at - London Stock Exchange

Intraday Poolbeg Pharma Share Chart

Form 8.5 (EPT/RI) - Poolbeg Pharma Plc

6 Feb 2025 10:36

Form 8.5 (EPT/RI) - Poolbeg Pharma Plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Name of exempt principal trader:Shore Capital Stockbrokers Ltd
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereePoolbeg Pharma Plc
(c) Name of the party to the offer with which exempt principal trader is connected:Poolbeg Pharma Plc
(d) Date dealing undertaken:05 February 2025
(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?No

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid/receivedLowest price per unit paid/received
OrdinaryPurchases100,0005.121p5.121p
OrdinarySales6,2005.16p5.156p

(b) Derivatives transactions (other than option)

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
     

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit
        

(ii) Exercising

Class of relevant securityProduct description e.g. call optionNumber of securitiesExercise price per unit
    

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)
    

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure:06 February 2025
Contact name:Laura Parmenter
Telephone number:0207 647 8154

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
9th Jan 20254:28 pmRNSForm 8.5- Poolbeg Pharma PLC
9th Jan 202511:01 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
9th Jan 20258:53 amRNSForm 8.5 (EPT/NON-RI)
9th Jan 20257:00 amRNSHolding(s) in Company
8th Jan 20253:56 pmRNSForm 8.5 (EPT/NON-RI) - Poolbeg Pharma PLC
8th Jan 20253:53 pmRNSForm 8 (OPD) - Poolbeg Pharma plc
8th Jan 202510:51 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
8th Jan 20259:44 amRNSForm 8.5 (EPT/NON-RI)
7th Jan 202510:54 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
7th Jan 202510:48 amRNSForm 8.5 (EPT/NON-RI)
7th Jan 20257:00 amRNSUpdate Potential Combination of Poolbeg & HOOKIPA
6th Jan 202510:27 amRNSForm 8.5 (EPT/NON-RI)
6th Jan 202510:19 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
3rd Jan 202511:40 amRNSForm 8.5 (EPT/NON-RI)
3rd Jan 202511:34 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
2nd Jan 20257:00 amRNSCombination of Poolbeg and HOOKIPA Pharma Inc.
20th Nov 20247:00 amRNSPOLB 001 Patent Granted in United States
18th Sep 20247:00 amRNSInterim results for the six months to 30 June 2024
12th Aug 20241:28 pmRNSHolding(s) in Company
26th Jul 20247:00 amRNSVoluntary Delisting from OTCQB Market
10th Jul 20247:00 amRNSNotification of Major Holdings
2nd Jul 20247:00 amRNSChange of Registered Address
17th Jun 20248:38 amRNSResult of AGM
9th May 20247:00 amRNSAnnual Report & AGM Notice
1st May 20247:00 amRNSSignificant POLB 001 Patent Granted in USA
30th Apr 20247:02 amRNSAppointment of Joint Broker
30th Apr 20247:01 amRNSOption Agreement to Acquire Orphan Drug Candidate
30th Apr 20247:00 amRNSResults for the year ended 31 December 2023
29th Apr 20247:00 amRNSTR-1: Notification of major holdings
22nd Feb 20247:00 amRNSDirector/PDMR Shareholding
19th Feb 20241:42 pmRNSDirector Share Purchase
15th Feb 20247:00 amRNSBoard Role Change and Launch of EIP
17th Jan 20247:00 amRNSFurther data shows POLB001 potential in cancer CRS
20th Dec 20237:00 amRNSRSV AI Drug Candidate Analysis Update
11th Dec 20237:00 amRNSPOLB 001 Data Presented at ASH
30th Nov 20237:00 amRNSDirectorate Change
21st Nov 20237:00 amRNSImmunomodulator II patent granted in Japan
16th Nov 20237:00 amRNSPOLB 001 LPS Trial Data to be Presented at IUIS
9th Nov 20237:00 amRNSFormer Amryt Pharma Leadership Team join Poolbeg
3rd Nov 20237:05 amRNSPOLB001 Data to be Presented at ASH Annual Meeting
1st Nov 20237:00 amRNSPOLB 001 Oncology Programme Update Meeting
26th Oct 20237:00 amRNSSAB Endorses Influenza Drug Targets
17th Oct 20237:00 amRNSPoolbeg Partners with a Nasdaq-Listed Biopharma
29th Sep 20237:00 amRNSFavourable Conclusion of Patent Opposition
20th Sep 20237:00 amRNSImmunomodulator I Patent Portfolio Strengthened
19th Sep 20237:00 amRNSImmunomodulator I Patent Opposition Withdrawal
13th Sep 20237:00 amRNSInterim results for the six months to 30 June 2023
29th Jun 20237:00 amRNSAI led programme identifies influenza drug targets
22nd Jun 20237:00 amRNSOral Vaccine Programme Moves Forward
24th May 20237:00 amRNSBoard Appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.